Merck

132 results

The Four Courts. Pharma  giant Merck Sharp and Dohme had last April secured a temporary High Court injunction preventing rival Clonmel Healthcare continuing to sell a version of MSD’s “Inegy” drug. Photograph: Bryan O’Brien

The Court of Appeal has refused to grant an injunction preventing distribution of a generic alternative to a cholesterol-reducing drug at less than on(...)

Eli Lilly & Co: “We are deeply disappointed for the millions suffering from this devastating disease.” Photograph: Simone Baribeau/Bloomberg

Eli Lilly and AstraZeneca ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of (...)

Pharmaceutical giant Merck Sharp and Dohme (MSD) last month got a temporary High Court injunction preventing rival Clonmel Healthcare from continue to sell a version of MSD’s “Inegy” drug over alleged breach of trademark.

The Court of Appeal will give a decision later on whether to grant an injunction preventing the distribution of a generic alternative to a cholesterol(...)

Merck reported a better-than-expected first-quarter profit on Tuesday, helped by a rise of more than 150 per cent in sales of cancer drug Keytruda.

Drugmaker Merck reported a better-than-expected first-quarter profit on Tuesday, helped by a rise of more than 150 per cent in sales of cancer drug Ke(...)

More than 3,000 representatives from major construction companies, developers and property managers are expected to attend the National Construction Summit on Wednesday. Photograph: Alan Betson

MONDAY Results: McDonalds. Indicators: Euro-zone loan growth (Mar); German retail sales (Mar), inflation (Apr). TUESDAY Results: Trinity Biotec(...)

Floor of NYSE on Monday, April 23th. Photograph: Michael Nagle/Bloomberg

European shares edged up on Monday as a rise in US Treasury yields helped lift bank stocks to nearly five-week highs, more than offsetting a disappoin(...)

MSD has told the court that Clonmel Healthcare, part of Stada AG publicly quoted group based in Germany, is infringing its patent rights. Photograph: Robbie Reynolds

A rival of pharmaceutical giant MSD is trying to sell a generic version of a cholesterol drug for less than one tenth of the price of its product in b(...)

Takeda said it offered had £46.50 (€53.46) a share in cash and stock last week for Shire in a bid to extend its global reach.

Shire shares surged following a report that Allergan is considering a bid for the drugmaker to compete with Takeda Pharmaceutical’s $60 billion (€48,(...)

Artist’s impression of new MSD site at Swords, expanded  to 43,000sq m from previous 31,000sq m plant.

MSD has submitted planning permission for the construction of its major new biotech plant in Swords. The company’s new biologics facility will be bu(...)

Traders at the New York Stock Exchange on Monday. US stocks rose on Monday, boosted by healthcare stocks and on easing fears that the US-led missile attack on Syria would escalate. Photograph: Michael Nagle/Bloomberg

European shares fell on Monday as investors awaited new US sanctions on Russia, while losses were limited as the market expected there would be no imm(...)

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
  • Last »